A neuroimaging biomarker for striatal dysfunction in schizophrenia
文献类型:期刊论文
; | |
作者 | Li, Ang1,2,3,4; Zalesky, Andrew5,6,7; Yue, Weihua8,9,10; Howes, Oliver11,12; Yan, Hao8,9,10; Liu, Yong1,2,3,4; Fan, Lingzhong1,2,3,4; Whitaker, Kirstie J.13,14; Xu, Kaibin1,2,3; Rao, Guangxiang1,2,3,4 |
刊名 | NATURE MEDICINE ; NATURE MEDICINE |
出版日期 | 2020-03-23 ; 2020-03-23 |
卷号 | 26期号:26页码:27 |
ISSN号 | 1078-8956 ; 1078-8956 |
关键词 | TREATMENT-RESISTANT SCHIZOPHRENIA,RESTING-STATE FMRI,FUNCTIONAL CONNECTIVITY,DOPAMINE HYPOTHESIS,GENE-EXPRESSION,NETWORK TREATMENT-RESISTANT SCHIZOPHRENIA,RESTING-STATE FMRI,FUNCTIONAL CONNECTIVITY,DOPAMINE HYPOTHESIS,GENE-EXPRESSION,NETWORK |
DOI | 10.1038/s41591-020-0793-8 ; 10.1038/s41591-020-0793-8 |
通讯作者 | Jiang, Tianzi(Jiangtz@nlpr.ia.ac.cn) ; Liu, Bing(bliu@nlpria.ac.cn) |
英文摘要 | Mounting evidence suggests that function and connectivity of the striatum is disrupted in schizophrenia(1-5). We have developed a new hypothesis-driven neuroimaging biomarker for schizophrenia identification, prognosis and subtyping based on functional striatal abnormalities (FSA). FSA scores provide a personalized index of striatal dysfunction, ranging from normal to highly pathological. Using inter-site cross-validation on functional magnetic resonance images acquired from seven independent scanners (n = 1,100), FSA distinguished individuals with schizophrenia from healthy controls with an accuracy exceeding 80% (sensitivity, 79.3%; specificity, 81.5%). In two longitudinal cohorts, inter-individual variation in baseline FSA scores was significantly associated with antipsychotic treatment response. FSA revealed a spectrum of severity in striatal dysfunction across neuropsychiatric disorders, where dysfunction was most severe in schizophrenia, milder in bipolar disorder, and indistinguishable from healthy individuals in depression, obsessive-compulsive disorder and attention-deficit hyperactivity disorder. Loci of striatal hyperactivity recapitulated the spatial distribution of dopaminergic function and the expression profiles of polygenic risk for schizophrenia. In conclusion, we have developed a new biomarker to index striatal dysfunction and established its utility in predicting antipsychotic treatment response, clinical stratification and elucidating striatal dysfunction in neuropsychiatric disorders. A new cross-validated neuroimaging biomarker that reflects striatal dysfunctioning can be used to distinguish patients with schizophrenia from healthy controls, and is associated with treatment response to antipsychotics. ;Mounting evidence suggests that function and connectivity of the striatum is disrupted in schizophrenia(1-5). We have developed a new hypothesis-driven neuroimaging biomarker for schizophrenia identification, prognosis and subtyping based on functional striatal abnormalities (FSA). FSA scores provide a personalized index of striatal dysfunction, ranging from normal to highly pathological. Using inter-site cross-validation on functional magnetic resonance images acquired from seven independent scanners (n = 1,100), FSA distinguished individuals with schizophrenia from healthy controls with an accuracy exceeding 80% (sensitivity, 79.3%; specificity, 81.5%). In two longitudinal cohorts, inter-individual variation in baseline FSA scores was significantly associated with antipsychotic treatment response. FSA revealed a spectrum of severity in striatal dysfunction across neuropsychiatric disorders, where dysfunction was most severe in schizophrenia, milder in bipolar disorder, and indistinguishable from healthy individuals in depression, obsessive-compulsive disorder and attention-deficit hyperactivity disorder. Loci of striatal hyperactivity recapitulated the spatial distribution of dopaminergic function and the expression profiles of polygenic risk for schizophrenia. In conclusion, we have developed a new biomarker to index striatal dysfunction and established its utility in predicting antipsychotic treatment response, clinical stratification and elucidating striatal dysfunction in neuropsychiatric disorders. A new cross-validated neuroimaging biomarker that reflects striatal dysfunctioning can be used to distinguish patients with schizophrenia from healthy controls, and is associated with treatment response to antipsychotics. |
WOS关键词 | TREATMENT-RESISTANT SCHIZOPHRENIA ; TREATMENT-RESISTANT SCHIZOPHRENIA ; RESTING-STATE FMRI ; FUNCTIONAL CONNECTIVITY ; DOPAMINE HYPOTHESIS ; GENE-EXPRESSION ; NETWORK ; PSYCHOSIS ; RISK ; DYSCONNECTIVITY ; DISORDER ; RESTING-STATE FMRI ; FUNCTIONAL CONNECTIVITY ; DOPAMINE HYPOTHESIS ; GENE-EXPRESSION ; NETWORK ; PSYCHOSIS ; RISK ; DYSCONNECTIVITY ; DISORDER |
资助项目 | National Key Basic Research and Development Program (973)[2011CB707800] ; National Key Basic Research and Development Program (973)[2011CB707800] ; National Key Research and Development Plan[2016YFC0904300] ; Strategic Priority Research Program of Chinese Academy of Science[XDB32020200] ; Natural Science Foundation of China[81771451] ; National Key Research and Development Plan[2016YFC0904300] ; Strategic Priority Research Program of Chinese Academy of Science[XDB32020200] ; Natural Science Foundation of China[81771451] |
WOS研究方向 | Biochemistry & Molecular Biology ; Biochemistry & Molecular Biology ; Cell Biology ; Research & Experimental Medicine ; Cell Biology ; Research & Experimental Medicine |
语种 | 英语 ; 英语 |
出版者 | NATURE PUBLISHING GROUP ; NATURE PUBLISHING GROUP |
WOS记录号 | WOS:000521529700004 ; WOS:000521529700004 |
资助机构 | National Key Basic Research and Development Program (973) ; National Key Basic Research and Development Program (973) ; National Key Research and Development Plan ; Strategic Priority Research Program of Chinese Academy of Science ; Natural Science Foundation of China ; National Key Research and Development Plan ; Strategic Priority Research Program of Chinese Academy of Science ; Natural Science Foundation of China |
源URL | [http://ir.ia.ac.cn/handle/173211/38706] |
专题 | 自动化研究所_脑网络组研究中心 |
通讯作者 | Jiang, Tianzi; Liu, Bing |
作者单位 | 1.Chinese Acad Sci, Brainnetome Ctr, Beijing, Peoples R China 2.Chinese Acad Sci, Natl Lab Pattern Recognit, Inst Automat, Beijing, Peoples R China 3.Univ Chinese Acad Sci, Sch Artificial Intelligence, Beijing, Peoples R China 4.Chinese Acad Sci, Ctr Excellence Brain Sci & Intelligence Technol, Shanghai, Peoples R China 5.Univ Melbourne, Dept Psychiat, Melbourne Neuropsychiat Ctr, Melbourne, Vic, Australia 6.Melbourne Hlth, Melbourne, Vic, Australia 7.Univ Melbourne, Dept Biomed Engn, Melbourne, Vic, Australia 8.Peking Univ, Sixth Hosp, Inst Mental Hlth, Beijing, Peoples R China 9.Peking Univ, Sixth Hosp, Minist Hlth, Key Lab Mental Hlth, Beijing, Peoples R China 10.Peking Univ, Sixth Hosp, Natl Clin Res Ctr Mental Disorders, Beijing, Peoples R China |
推荐引用方式 GB/T 7714 | Li, Ang,Zalesky, Andrew,Yue, Weihua,et al. A neuroimaging biomarker for striatal dysfunction in schizophrenia, A neuroimaging biomarker for striatal dysfunction in schizophrenia[J]. NATURE MEDICINE, NATURE MEDICINE,2020, 2020,26(26):27, 27. |
APA | Li, Ang.,Zalesky, Andrew.,Yue, Weihua.,Howes, Oliver.,Yan, Hao.,...&Liu, Bing.(2020).A neuroimaging biomarker for striatal dysfunction in schizophrenia.NATURE MEDICINE,26(26),27. |
MLA | Li, Ang,et al."A neuroimaging biomarker for striatal dysfunction in schizophrenia".NATURE MEDICINE 26.26(2020):27. |
入库方式: OAI收割
来源:自动化研究所
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。